Stock Information

• Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?
  Wed, Apr 15, 2026 6:32 PM
• Neurocrine Biosciences : 2026 Proxy Statement (NBIX 2026 Proxy Statement)
  Wed, Apr 15, 2026 5:16 PM
• Neurocrine Biosciences : 2025 Annual Report*
  Wed, Apr 15, 2026 5:14 PM
• Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
  Tue, Apr 14, 2026 8:01 PM
• Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
  Tue, Apr 14, 2026 12:30 PM
• Neurocrine Biosciences Announces Tardive Dyskinesia Patients Treated With Its INGREZZA Capsules Demonstrated Higher Treatment Persistence Compared To AUSTEDO XR
  Tue, Apr 14, 2026 8:42 AM
• Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
  Mon, Apr 13, 2026 3:28 AM
• Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
  Sun, Apr 12, 2026 11:30 PM
• Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc. - M&A Call - Slideshow
  Fri, Apr 10, 2026 7:04 PM
• Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185
  Fri, Apr 10, 2026 11:35 AM

Financial data not available